Adriana Bourne, PA
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,169 of the $2,712 with a category attached, or 80.0%. 29 manufacturers reported payments, led by Teleflex LLC at 32.0% of the total. Among surgical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$868
- Coloplast$258
- Dendreon Pharmaceuticals LLC$250
- Merck$206
- Urogen Pharma, Inc.$191
- AbbVie$107
- plus $832 from 23 others
What the payments were for
- Travel & lodging$54420%
- Food & beverage$2,16980%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 3 | $868 |
| Coloplast | 8 | $258 |
| Dendreon Pharmaceuticals LLC | 5 | $250 |
| Merck | 7 | $206 |
| Urogen Pharma, Inc. | 7 | $191 |
| AbbVie | 6 | $107 |
| Johnson & Johnson | 5 | $87 |
| Sumitomo Pharma America, Inc. | 5 | $81 |
| Accord Healthcare, Inc. | 4 | $77 |
| Vertex | 3 | $74 |
| Genentech USA, Inc. | 7 | $71 |
| Boston Scientific | 1 | $55 |
| Myriad Genetic Laboratories, Inc. | 3 | $51 |
| Olympus America Inc. | 2 | $38 |
| Tolmar, Inc. | 2 | $32 |
| Immunitybio, Inc. | 2 | $30 |
| Verity Pharmaceuticals Inc. | 2 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Agiliti Surgical, Inc. | 1 | $19 |
| 180 Medical, Inc. | 1 | $18 |
| Civco Medical Instruments | 1 | $18 |
| Ambu Inc. | 18 | $17 |
| Blue Earth Diagnostics | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| Endo USA, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Photocure Inc | 1 | $14 |
| Valencia Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,712 in reported general payments places this provider in the 90th percentile of 229 surgical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 76 | $40,081 |
| GemtesaVibegron | 46 | $30,323 |
| Mirabegron ErMirabegron | 24 | $13,736 |
| Tamsulosin Hcl | 458 | $6,399 |
| Trospium Chloride ErTrospium Chloride | 20 | $4,904 |
| Trospium Chloride | 50 | $3,845 |
| Oxybutynin Chloride ErOxybutynin Chloride | 158 | $2,838 |
| Methenamine Hippurate | 27 | $1,610 |
| Finasteride | 91 | $1,547 |
| Cephalexin | 88 | $1,360 |
| NitrofurantoinNitrofurantoin Macrocrystal | 22 | $849 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 80 | $748 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $675 |
| Imipramine Hcl | 11 | $465 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $81 | $30,32346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 229 surgical providers in Michigan.
Other surgical in Flint
- Kathryn LeggieriFlint$2K
- Stephanie LamontFlint$1K
- Jessica HumphreyRedford Twp$225K
- Michael BaldwinDearborn$12K
- Leslie NicholsWoodhaven$11K
- Lisa BrownBay City$10K
- Lauren VandenbergThree Rivers$9K
- Sara FukuzawaRoyal Oak$5K
- Krista McCarverNovi$4K
- Deborah NobaniClinton Township$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.